Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation and get cracking. For those who track this sort of behavior, we are brewing, once again, the oh-so-seasonal pumpkin spice. Meanwhile, do keep us in mind if you hear anything interesting. Have a smashing day …

The number of new clinical trials started in the U.K. last year was 25 percent lower than the average for 2009-16, as anxiety about the Brexit impact on future medicines regulation made companies hesitate about running studies in the country, Reuters explains. A total of 597 trials were initiated in the U.K. in 2017, against an average of 806 over the previous eight years. The pharmaceuticals industry has long warned that Brexit could have a serious impact on research and access to medicines, unless London and Brussels reach a deal for regulatory continuity.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy